
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded capsule containing mesalamine, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing mesalamine are listed in capsule, tablet, suppository, suspension and enema forms. It is also a component of FDA-approved kits.
This is a solid, nonaqueous dose form. Under USP <795>, nonaqueous preparations carry longer default beyond-use dates than water-containing ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Mesalamine (5-aminosalicylic acid) is an aminosalicylate anti-inflammatory; compounding pharmacies prepare it as rectal enemas, suppositories and oral forms by prescription.
Mesalamine, also called 5-aminosalicylic acid or 5-ASA, is an aminosalicylate. Its mechanism is not fully understood; it appears to act topically on the lining of the colon, possibly by blocking cyclooxygenase and lipoxygenase pathways and reducing prostaglandin and leukotriene production. Manufactured products include Lialda delayed-release tablets (Takeda), FDA-approved to induce and maintain remission of mildly to moderately active ulcerative colitis in adults and to treat it in children above a minimum weight; Pentasa capsules (Takeda) and Apriso extended-release capsules (Salix); Canasa suppositories (Allergan), approved for mildly to moderately active ulcerative proctitis in adults; and Rowasa rectal suspension enema (Viatris), approved for active mild to moderate distal ulcerative colitis, proctosigmoiditis or proctitis in adults. Prescribers may order mesalamine compounded for a rectal strength, volume or vehicle that is not manufactured. Compounded preparations are not FDA-approved and require a prescription.
Mesalamine labels carry no boxed warning. Do not use it if you are allergic to salicylates such as aspirin, to aminosalicylates or to any ingredient; Rowasa also lists sulfites. Kidney problems, including interstitial nephritis and rarely kidney failure, have been reported, so kidney function is checked during treatment. An acute intolerance reaction, with cramping, abdominal pain, bloody diarrhea and sometimes fever, headache and rash, can look like a colitis flare. Other warnings include allergic heart inflammation (myocarditis or pericarditis), liver failure in people with liver disease, serious skin reactions, kidney stones and sun sensitivity. NSAIDs and other kidney-toxic drugs, and azathioprine or 6-mercaptopurine, add risk. MedlinePlus advises against taking mesalamine within six weeks after a chickenpox vaccine. LactMed and the Lialda label report small amounts in breast milk and occasional infant diarrhea and advise watching a nursing infant for diarrhea. Talk to your prescriber or pharmacist about side effects.
Mesalamine is thought to act locally on colonic epithelium; proposed mechanisms include cyclooxygenase and lipoxygenase inhibition, reduced NF-kB activity and free radical scavenging (StatPearls). Systemic absorption depends on the product: about 21 to 22 percent after Lialda, with plasma levels peaking late as the tablet releases in the colon, while rectal suppositories distribute locally without plasma accumulation (StatPearls). Mesalamine is acetylated by N-acetyltransferase, mainly NAT-1, in the liver and intestinal mucosa to N-acetyl-5-ASA, is about 43 percent protein bound, and is excreted mainly in urine as the metabolite; terminal half-lives after Lialda average 7 to 9 hours for mesalamine and 8 to 12 hours for the metabolite, and exposure rises as renal function falls. Labeled indications: Lialda (adult and pediatric ulcerative colitis), Canasa (ulcerative proctitis), Rowasa (distal ulcerative colitis, proctosigmoiditis, proctitis). StatPearls notes rectal 5-ASA is preferred first-line for distal disease, with suppositories for rectal disease and enemas when inflammation extends to the sigmoid colon. Dosing is per prescriber. Monitor renal function at baseline and periodically, CBC and platelets with thiopurines, and hydration, since mesalamine stones are radiolucent; mesalamine can falsely raise urinary normetanephrine measured by liquid chromatography with electrochemical detection. Mesalamine is not a controlled substance.
Swallow each capsule whole with a glass of water, unless your label says otherwise. Do not crush, chew or open the capsule unless your pharmacist tells you it is safe to do so. Take it at the times shown on your prescription label. If you miss a dose or are unsure how to take it, call the pharmacy.
Capsules are nonaqueous, so under USP <795> they usually carry a beyond-use date of up to 180 days when no other stability data apply. Keep the vial tightly closed at room temperature, away from heat, moisture and direct light, and out of reach of children. Discard any capsules left after the beyond-use date on the label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take 1 capsule by mouth